Integra LifeSciences (IART) Tops Q3 EPS by 3c; offers guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.59, $0.03 better than the analyst estimate of $0.56. Revenue for the quarter came in at $411.2 million versus the consensus estimate of $414.25 million.

GUIDANCE:

Integra LifeSciences sees Q4 2026 EPS of $0.61-$0.71, versus the consensus of $0.73. Integra LifeSciences sees Q4 2026 revenue of $413-433 million, versus the consensus of $432.21 million.

Integra LifeSciences sees FY2026 EPS of $2.30-$2.40, versus the consensus of $2.38. Integra LifeSciences sees FY2026 revenue of $1.634-1.654 billion, versus the consensus of $1.66 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Users Reporting Some Usage Restored to ThinkOrSwim and Schwab Mobile/Desktop Platform
• Raymond James Reiterates Market Perform Rating on Byline Bancorp (BY)
• Yara International ASA (YAR:NO) (YARIY) PT Lowered to NOK425 at Berenberg